Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching RMB 1.2 billion for the fiscal year 2024[2]. - Revenue for the year ended December 31, 2024, was RMB 2,018,334 thousand, a decrease of 15.06% compared to RMB 2,376,487 thousand in 2023[17]. - Gross profit for 2024 was RMB 505,540 thousand, reflecting a gross margin of 25.05%, down from 41.21% in 2023[17]. - Net profit for the year was RMB 69,755 thousand, a significant decline of 82.16% from RMB 391,553 thousand in 2023[17]. - Total assets as of December 31, 2024, amounted to RMB 9,396,152 thousand, down from RMB 10,027,159 thousand in 2023[17]. - Total liabilities decreased to RMB 1,316,964 thousand in 2024 from RMB 1,746,118 thousand in 2023, indicating improved financial stability[17]. - The company's equity attributable to shareholders was RMB 8,078,818 thousand, slightly down from RMB 8,279,316 thousand in 2023[17]. - Basic earnings per share for 2024 was RMB 0.10, a decrease from RMB 0.53 in 2023[17]. - The company reported a net profit of RMB 69.8 million for the year ended December 31, 2024, a decrease of 82.2% from RMB 391.6 million in 2023, resulting in a net profit margin drop to 3.5%[60]. - Other income and losses netted RMB 161.2 million in 2024, a decrease of 33.0% from RMB 240.5 million in 2023, primarily due to reduced interest income[52]. Market and Growth Strategy - The company provided a positive outlook for 2025, projecting a revenue growth of 10% to 12%[2]. - New product launches are expected to contribute an additional RMB 300 million in revenue next year[2]. - Market expansion plans include entering two new international markets by Q3 2025[2]. - The company aims to increase its market share by 3% in the next fiscal year through targeted marketing strategies[2]. - Future outlook includes potential market expansion and strategic partnerships to drive growth in the biopharmaceutical sector[12]. - The company plans to explore mergers and acquisitions to strengthen its market position and enhance its technological capabilities[12]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the biotechnology sector[104]. - Market expansion plans include entering three new international markets by the end of 2025, targeting a 10% market share in each[104]. Research and Development - The company is investing RMB 200 million in R&D for new technologies aimed at enhancing product offerings[2]. - The company is focusing on research and development in antibody-drug conjugates (ADC) and CAR-T cell therapies to enhance its product pipeline[12]. - The company has established a key technology platform for biotechnology drug quality research, having applied for and published 12 patents in this area[40]. - The company has enhanced its in vitro metabolism platform for small molecule drugs, establishing MSD detection methods for oligonucleotide drugs and mass spectrometry methods for ADC drugs, covering various drug types including antibodies and gene therapy products[28]. - The company is committed to advancing innovative experimental models and organoid applications, particularly in tumor research and new drug development[86]. - The company plans to develop innovative non-human primate disease models, focusing on aging-related diseases such as obesity and diabetes, to support drug screening and preclinical evaluation[86]. Operational Efficiency - The management highlighted a focus on improving operational efficiency, targeting a 5% reduction in costs by the end of 2025[2]. - The board of directors highlighted the successful implementation of cost-cutting measures, resulting in a 5% reduction in operational expenses[104]. - The company aims to enhance operational efficiency and service quality through various innovative initiatives[18]. - The company is actively seeking strategic investment opportunities to enhance product R&D, product portfolio, channel expansion, and cost control[74]. Compliance and Risk Management - Compliance with various legal and regulatory requirements is critical; failure to adhere could adversely affect the company's reputation, business, financial condition, and future prospects[87]. - The company has maintained compliance with all relevant laws and regulations, with no significant legal issues reported during the period[121]. - The company complies with anti-bribery and anti-corruption regulations to mitigate risks associated with bribery and corruption[196]. - The company faces risks from fluctuating international economic conditions and reduced investment in pharmaceutical innovation, which may impact international business revenue and foreign exchange losses[87]. Human Resources and Talent Management - The company has formed a professional service team of 2,652 members as of December 31, 2024, to improve management levels and service efficiency[44]. - The company is committed to maintaining effective communication with shareholders through various channels, including shareholder meetings and corporate communications[198]. - The company recruits and retains talented employees through a comprehensive training system aimed at enhancing technical expertise and service quality[195]. - The company has an urgent need for talent in management, technology, and marketing due to business expansion, with challenges in attracting and retaining qualified personnel amid rising competition and costs[87]. Shareholder and Financial Management - The company proposed a final dividend of RMB 0.03 per share for the fiscal year ending December 31, 2024, down from RMB 0.16 in 2023, resulting in a total proposed dividend amount of approximately RMB 22.39 million compared to RMB 119.98 million in the previous year[115]. - As of December 31, 2024, the company's distributable reserves amounted to RMB 822.2 million[126]. - The company has repurchased a total of 2,656,100 A-shares in 2024, with a total transaction amount of RMB 42,658,273.40 (excluding transaction fees)[128]. - The company has no significant investments, acquisitions, or disposals during the reporting period[70]. Client and Supplier Relations - The company served approximately 852 clients, including blue-chip pharmaceutical companies and small to medium-sized biotech firms as of December 31, 2024[187]. - The largest customer accounted for 2.87% of the group's total revenue, while the top five customers represented 11.76% of total revenue[199]. - The company has established stable relationships with numerous major suppliers located in China[191]. - There were no significant complaints from clients regarding the company's services or products during the reporting period[190].

港股创新药板块盘初走高，泰凌医药(01011.HK)涨近7%，石药集团(01093.HK)涨超4%，百济神州 (06160.HK)、昭衍新药(06127.HK)、药明生物(02269.HK)纷纷上涨。 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2025-017 北京昭衍新药研究中心股份有限公司 第四届董事会第十四次会议决议公告 公司董事会同意续聘毕马威华振会计师事务所（特殊普通合伙）为公司 2025 年度境内审计机构和内控审计机构；续聘毕马威会计师事务所为公司 2025 年度 境外财务审计机构。 表决结果：董事会以 9 票赞成、0 票反对、0 票弃权的表决结果通过该议案， 同意将该议案提交 2024 年度股东大会审议。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）及公司 指定信息披露媒体《上海证券报》披露的《昭衍新药关于续聘 2025 年度会计师 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京昭衍新药研究中心股份有限公司（以下简称"公司"或"昭衍新药"）第四 届董事会第十四次会议于 2025 年 4 月 24 日以书面送达、电子邮件等方式发出会 议通知，并于 2025 年 4 月 28 日以现场结合电话会议的形式召开。本次会议应参 加董事 9 人，实际参加董事 9 人，会议由董 ...

前十大流通股东累计持有： 45893.43万股，累计占流通股比： 61.22%，较上期变化： 1356.72万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 冯宇霞 | 16716.06 | 22.30 | 不变 | | HKSCC NOMINEES LIMITED | 11897.56 | 15.87 | 0.05 | | 周志文 | 7472.60 | 9.97 | 不变 | | 顾晓磊 | 2042.05 | 2.72 | 不变 | | 香港中央结算有限公司 | 1771.98 | 2.36 | 1040.89 | | 左从林 | 1409.83 | 1.88 | 不变 | | 易方达医疗保健行业混合A | 1383.24 | 1.85 | 139.80 | | 华宝中证医疗ETF | 1238.63 | 1.65 | -2.89 | | 顾美芳 | 1032.20 | 1.38 | 不变 | | 全国社保基金一零九组合 | 929.28 | 1.24 | 新进 | | | 较上个报告期退出前十大股东有 | ...

证券代码：603127 证券简称：昭衍新药 公告编号：2025-019 北京昭衍新药研究中心股份有限公司 关于召开 2025 年度第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 三、 参加人员 公司总经理、董事会秘书高大鹏先生，财务总监于爱水女士，独立董事张帆 先生。 四、 投资者参加方式 （一）投资者可于 2025 年 5 月 22 日（星期四）16:00-17:00，通过互联网登 录上证路演中心（https://roadshow.sseinfo.com/），在线参与本次业绩说明会，公 司将及时回答投资者的提问。 投资者可于 2025 年 5 月 16 日（星期五） 至 5 月 22 日（星期四）16:00 前 登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 jiafengsong@joinn-lab.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 北京昭衍新药研究中心股份有限公司（以下简称 ...

Financial Performance - The company's operating revenue for Q1 2025 was RMB 287.34 million, a decrease of 11.54% compared to RMB 324.81 million in the same period last year[4]. - Net profit attributable to shareholders was RMB 41.12 million, a significant increase of 115.11% from a loss of RMB 272.22 million in the previous year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 25.66 million, up 109.14% from a loss of RMB 280.67 million in the same period last year[4]. - Basic and diluted earnings per share were both RMB 0.05, reflecting an increase of 113.89% from a loss of RMB 0.36 per share in the same period last year[4]. - Operating profit for Q1 2025 was CNY 49,382,588.17, a significant recovery from a loss of CNY 293,008,274.73 in Q1 2024[23]. - Net profit for Q1 2025 reached CNY 41,119,465.25, compared to a net loss of CNY 273,363,603.07 in Q1 2024, marking a turnaround[23]. Cash Flow and Assets - The net cash flow from operating activities decreased by 45.69%, amounting to RMB 65.15 million compared to RMB 119.95 million in the previous year[4]. - Cash flow from operating activities in Q1 2025 was CNY 65,149,201.16, down from CNY 119,953,519.31 in Q1 2024[27]. - Cash inflow from investment activities in Q1 2025 was CNY 617,613,712.48, a substantial increase from CNY 111,453,520.72 in Q1 2024[27]. - Cash outflow from investment activities in Q1 2025 was CNY 951,573,490.95, compared to CNY 179,015,819.37 in Q1 2024, indicating increased investment[27]. - Cash and cash equivalents decreased from RMB 965.2 million to RMB 676.6 million, a decline of approximately 29.9%[17]. - The ending balance of cash and cash equivalents was $676,571,156.45, down from $2,865,314,156.35 at the beginning of the period[28]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 9.42 billion, a slight increase of 0.30% from RMB 9.40 billion at the end of the previous year[5]. - Total assets amounted to CNY 9,424,658,609.52, slightly up from CNY 9,396,152,610.45 in the previous period[20]. - Total current assets increased slightly from RMB 5.03 billion to RMB 5.06 billion, an increase of about 0.6%[18]. - Total current liabilities decreased from RMB 1.11 billion to RMB 1.10 billion, a reduction of about 0.8%[19]. - Non-current liabilities increased from RMB 206.4 million to RMB 217.8 million, an increase of approximately 5.7%[19]. - Total liabilities were CNY 1,315,452,686.46, showing a minor decrease from CNY 1,316,964,356.49[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,730[13]. - The company has a significant shareholder, Feng Yuxia, holding 22.30% of shares[13]. - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending[14]. Market Activity - The new signed orders amount to approximately RMB 430 million during the reporting period, with a total backlog of RMB 2.2 billion[15]. - The company is focused on expanding its market presence and enhancing its product offerings[15]. Non-Recurring Items - Non-recurring gains and losses amounted to RMB 15.46 million, with government subsidies contributing RMB 4.93 million[9]. - The net profit from laboratory services was a loss of RMB 41.34 million, a decline of 96.47% year-on-year, primarily due to intensified industry competition[5]. - The company reported a net gain of RMB 50.38 million from changes in the fair value of biological assets during the reporting period[5]. Return on Assets - The weighted average return on net assets increased by 3.86 percentage points to 0.51% compared to -3.35% in the previous year[4].

证券代码：603127 证券简称：昭衍新药 公告编号：2025-019 北京昭衍新药研究中心股份有限公司 关于续聘 2025 年度会计师事务所的公告 重要内容提示： 拟聘任的 2025 年度境内会计师事务所名称：毕马威华振会计师事务所 （特殊普通合伙）。 一、 拟续聘境内会计师事务所的基本情况 (一) 机构信息 1. 基本信息 毕马威华振会计师事务所于 1992 年 8 月 18 日在北京成立，于 2012 年 7 月 5 日获财政部批准转制为特殊普通合伙的合伙制企业，更名为毕马威华振会计师 事务所（特殊普通合伙）（以下简称"毕马威华振"），2012 年 7 月 10 日取得工商 营业执照，并于 2012 年 8 月 1 日正式运营。 毕马威华振总所位于北京，注册地址为北京市东城区东长安街 1 号东方广场 东 2 座办公楼 8 层。 毕马威华振的首席合伙人邹俊，中国国籍，具有中国注册会计师资格。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 于 2024 年 12 月 31 日，毕马威华振有合伙人 241 人，注册会计师 1 ...

Financial Performance - The company's operating revenue for Q1 2025 was RMB 287.34 million, a decrease of 11.54% compared to RMB 324.81 million in the same period last year[7]. - Net profit attributable to shareholders for Q1 2025 was RMB 41.12 million, a significant increase of 115.11% from a loss of RMB 272.22 million in the previous year[7]. - Basic and diluted earnings per share for Q1 2025 were RMB 0.05, a turnaround from a loss of RMB 0.36 per share in the previous year, representing an increase of 113.89%[7]. - The weighted average return on equity increased by 3.86 percentage points to 0.51% compared to -3.35% in the same period last year[7]. - The net profit attributable to shareholders of the listed company increased by 115.11% compared to the same period last year, primarily due to significant losses from the fair value changes of biological assets in the previous year[16]. - The total comprehensive income for Q1 2025 was CNY 40,352,525.89, compared to a total comprehensive loss of CNY 272,499,809.53 in Q1 2024[30]. - Operating profit for Q1 2025 was CNY 49,382,588.17, a turnaround from an operating loss of CNY 293,008,274.73 in Q1 2024[28]. Cash Flow and Assets - The net cash flow from operating activities was RMB 65.15 million, down 45.69% from RMB 119.95 million in the same period last year[7]. - Cash and cash equivalents decreased to CNY 676,571,156.45 as of March 31, 2025, from CNY 965,203,128.59 at the end of 2024, a decline of 29.9%[22]. - The company’s cash flow management remains a priority, with a significant reduction in cash reserves noted[22]. - The cash and cash equivalents at the end of Q1 2025 were $676,571,156.45, a significant decrease from $2,865,314,156.35 in Q1 2024, reflecting a decline of about 76.4%[34]. - The net increase in cash and cash equivalents for Q1 2025 was -$288,629,929.27, contrasting with a positive increase of $11,667,128.38 in Q1 2024[34]. - The impact of exchange rate changes on cash and cash equivalents in Q1 2025 was -$1,154,223.86, compared to -$2,795,727.79 in Q1 2024, showing an improvement of approximately 58.7%[34]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,730[18]. - The top ten shareholders hold a total of 22.30% of shares, with the largest shareholder, Feng Yuxia, owning 167,160,633 shares[18]. - The company has not identified any related party relationships among the top ten shareholders, except for known familial connections[19]. Business Operations and Strategy - The laboratory services business contributed a net profit of RMB -41.34 million, a decline of 96.47% year-on-year, primarily due to increased industry competition[11]. - The company plans to enhance its laboratory services and financial management strategies to improve profitability amid competitive pressures[9]. - The company plans to focus on expanding its market presence and enhancing R&D efforts in the upcoming quarters[27]. - The company signed new orders worth approximately RMB 430 million during the reporting period, with a backlog of orders amounting to approximately RMB 2.2 billion at the end of the reporting period[20]. Non-Recurring Items - Non-recurring gains and losses for the reporting period amounted to RMB 15.46 million, with significant contributions from government subsidies and financial asset management[10][13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 25.66 million, an increase of 109.14% from a loss of RMB 280.67 million in the previous year[7]. - The non-recurring gains and losses totaled RMB 15,456,940.42, indicating significant impacts from various non-operating activities[14]. Costs and Expenses - Total operating costs for Q1 2025 were CNY 288,252,886.21, down from CNY 293,294,646.96 in Q1 2024, reflecting a reduction of 1.4%[27]. - R&D expenses for Q1 2025 amounted to CNY 23,027,883.99, slightly increasing from CNY 22,967,298.39 in Q1 2024[27]. - Other income for Q1 2025 was CNY 5,270,400.41, down from CNY 6,650,918.69 in Q1 2024[28]. - Investment income for Q1 2025 was CNY 1,235,855.96, a decline from CNY 6,972,038.25 in Q1 2024[28]. Market and Risk Awareness - The company emphasizes the need for investors to be aware of investment risks due to market environment changes and industry competition[20]. - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[20]. - The company did not apply new accounting standards or interpretations starting from 2025, indicating a stable accounting approach for the current reporting period[34].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 (2)關於召開2025年度第一季度業績說明會的公告 (3)關於續聘2025年度會計師事務所的公告 (4)第四屆董事會第十四次會議決議公告 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 附件為本公司於上海證券交易所網站刊登之 北京昭衍新藥研究中心股份有限公司 (1) 2025年第一季度報告 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年4月28日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 ...

Core Insights - The global and US innovative drug VC&PE financing amounts are expected to grow by 1.93% and 5.29% respectively in 2024, indicating a recovery in the innovative drug financing environment [1] - The demand for research and development in fields such as peptides and ADCs is strong, leading to an increase in outsourcing needs in these areas [1][2] Macro Perspective - The global innovative drug financing environment is recovering, with significant growth in the demand for innovative research in specific fields like peptides and ADCs, which is expected to enhance the CXO industry's outlook [1] - According to Crunchbase, the VC&PE financing for innovative drugs in 2024 shows positive growth, marking an improvement in the financing environment [1] Micro Perspective - CXO listed companies are seeing a recovery in new orders, with many companies like WuXi AppTec, WuXi Biologics, and others reporting a year-on-year increase of over 20% in new orders [3] - The production capacity of domestic CXO companies is mature, ensuring timely delivery of orders, which is expected to lead to double-digit revenue growth for several companies in 2025 [3] Target Companies - Recommended companies to watch include WuXi AppTec (603259.SH, 02359), WuXi Biologics (02269), WuXi AppTec (02268), Kelun Pharmaceutical (002821.SZ, 06821), and others [4]